Limits...
Dynamic changes in amino acid concentration profiles in patients with sepsis.

Su L, Li H, Xie A, Liu D, Rao W, Lan L, Li X, Li F, Xiao K, Wang H, Yan P, Li X, Xie L - PLoS ONE (2015)

Bottom Line: As the disease progressed further or with poor prognosis, the levels of the different amino acids gradually increased, decreased, or fluctuated over time.The serum concentrations of SAAs, especially taurine, exhibited weak negative correlations with the Sequential Organ Failure Assessment (SOFA) (r=-0.319) and Acute Physiology and Chronic Health Evaluation (APACHE) II (r=-0.325) scores.The areas under the receiver operating characteristic curves of cystine, taurine, and SAA levels and the SOFA and APACHE II scores, which denoted disease prognosis, were 0.623, 0.674, 0.678, 0.86, and 0.857, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Diseases, Chinese PLA General Hospital, Beijing, China; Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.

ABSTRACT

Objectives: The goal of this work was to explore the dynamic concentration profiles of 42 amino acids and the significance of these profiles in relation to sepsis, with the aim of providing guidance for clinical therapies.

Methods: Thirty-five critically ill patients with sepsis were included. These patients were further divided into sepsis (12 cases) and severe sepsis (23 cases) groups or survivor (20 cases) and non-survivor (15 cases) groups. Serum samples from the patients were collected on days 1, 3, 5, 7, 10, and 14 following intensive care unit (ICU) admission, and the serum concentrations of 42 amino acids were measured.

Results: The metabolic spectrum of the amino acids changed dramatically in patients with sepsis. As the disease progressed further or with poor prognosis, the levels of the different amino acids gradually increased, decreased, or fluctuated over time. The concentrations of sulfur-containing amino acids (SAAs), especially taurine, decreased significantly as the severity of sepsis worsened or with poor prognosis of the patient. The serum concentrations of SAAs, especially taurine, exhibited weak negative correlations with the Sequential Organ Failure Assessment (SOFA) (r=-0.319) and Acute Physiology and Chronic Health Evaluation (APACHE) II (r=-0.325) scores. The areas under the receiver operating characteristic curves of cystine, taurine, and SAA levels and the SOFA and APACHE II scores, which denoted disease prognosis, were 0.623, 0.674, 0.678, 0.86, and 0.857, respectively.

Conclusions: Critically ill patients with disorders of amino acid metabolism, especially of SAAs such as cystine and taurine, may provide an indicator of the need for the nutritional support of sepsis in the clinic.

Trial registration: ClinicalTrial.gov identifier NCT01818830.

No MeSH data available.


Related in: MedlinePlus

The dynamic changes in cystine (A), taurine (B), and sulfur-containing amino acid (C) levels between survivors and non-survivors on days 1, 3, 5, 7, 10, and 14.*P<0.05.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4388841&req=5

pone.0121933.g003: The dynamic changes in cystine (A), taurine (B), and sulfur-containing amino acid (C) levels between survivors and non-survivors on days 1, 3, 5, 7, 10, and 14.*P<0.05.

Mentions: To explore the metabolic dysfunction of patients with poor prognoses, we compared the serum concentrations of amino acids between survivors and non-survivors based on a 28-day survival (S4 Table). The serum concentrations of α-aminoadipic acid, cystathionine, ethanolamine, and phenylalanine in non-survivors at certain time points were higher and statistically significant (P<0.05). Compared with survivors, serum concentrations of arginine, glutamic acid, serine, taurine, and tryptophan, as well as the BCAA/AAA ratio, in non-survivors were significantly lower (P<0.05) at certain time points. Fig. 3 shows the trends in cystine (A), taurine (B), and SAA (C) serum concentrations.


Dynamic changes in amino acid concentration profiles in patients with sepsis.

Su L, Li H, Xie A, Liu D, Rao W, Lan L, Li X, Li F, Xiao K, Wang H, Yan P, Li X, Xie L - PLoS ONE (2015)

The dynamic changes in cystine (A), taurine (B), and sulfur-containing amino acid (C) levels between survivors and non-survivors on days 1, 3, 5, 7, 10, and 14.*P<0.05.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4388841&req=5

pone.0121933.g003: The dynamic changes in cystine (A), taurine (B), and sulfur-containing amino acid (C) levels between survivors and non-survivors on days 1, 3, 5, 7, 10, and 14.*P<0.05.
Mentions: To explore the metabolic dysfunction of patients with poor prognoses, we compared the serum concentrations of amino acids between survivors and non-survivors based on a 28-day survival (S4 Table). The serum concentrations of α-aminoadipic acid, cystathionine, ethanolamine, and phenylalanine in non-survivors at certain time points were higher and statistically significant (P<0.05). Compared with survivors, serum concentrations of arginine, glutamic acid, serine, taurine, and tryptophan, as well as the BCAA/AAA ratio, in non-survivors were significantly lower (P<0.05) at certain time points. Fig. 3 shows the trends in cystine (A), taurine (B), and SAA (C) serum concentrations.

Bottom Line: As the disease progressed further or with poor prognosis, the levels of the different amino acids gradually increased, decreased, or fluctuated over time.The serum concentrations of SAAs, especially taurine, exhibited weak negative correlations with the Sequential Organ Failure Assessment (SOFA) (r=-0.319) and Acute Physiology and Chronic Health Evaluation (APACHE) II (r=-0.325) scores.The areas under the receiver operating characteristic curves of cystine, taurine, and SAA levels and the SOFA and APACHE II scores, which denoted disease prognosis, were 0.623, 0.674, 0.678, 0.86, and 0.857, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Diseases, Chinese PLA General Hospital, Beijing, China; Department of Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.

ABSTRACT

Objectives: The goal of this work was to explore the dynamic concentration profiles of 42 amino acids and the significance of these profiles in relation to sepsis, with the aim of providing guidance for clinical therapies.

Methods: Thirty-five critically ill patients with sepsis were included. These patients were further divided into sepsis (12 cases) and severe sepsis (23 cases) groups or survivor (20 cases) and non-survivor (15 cases) groups. Serum samples from the patients were collected on days 1, 3, 5, 7, 10, and 14 following intensive care unit (ICU) admission, and the serum concentrations of 42 amino acids were measured.

Results: The metabolic spectrum of the amino acids changed dramatically in patients with sepsis. As the disease progressed further or with poor prognosis, the levels of the different amino acids gradually increased, decreased, or fluctuated over time. The concentrations of sulfur-containing amino acids (SAAs), especially taurine, decreased significantly as the severity of sepsis worsened or with poor prognosis of the patient. The serum concentrations of SAAs, especially taurine, exhibited weak negative correlations with the Sequential Organ Failure Assessment (SOFA) (r=-0.319) and Acute Physiology and Chronic Health Evaluation (APACHE) II (r=-0.325) scores. The areas under the receiver operating characteristic curves of cystine, taurine, and SAA levels and the SOFA and APACHE II scores, which denoted disease prognosis, were 0.623, 0.674, 0.678, 0.86, and 0.857, respectively.

Conclusions: Critically ill patients with disorders of amino acid metabolism, especially of SAAs such as cystine and taurine, may provide an indicator of the need for the nutritional support of sepsis in the clinic.

Trial registration: ClinicalTrial.gov identifier NCT01818830.

No MeSH data available.


Related in: MedlinePlus